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Abstract
Background: Few studies have focused on investigating hypoalbuminemia in patients during earlier stages of
chronic kidney disease (CKD). In particular, little is known about the role of gastrointestinal (GI) symptoms. Our goal
in this paper is to study how GI symptoms relate to serum albumin levels in CKD, especially in the context of and
compared with inflammation.
Methods: We performed a cross-sectional study of 3599 patients with chronic kidney disease enrolled in the Chronic
Renal Insufficiency Cohort (CRIC) study. All subjects were asked to complete the Modification of Diet in Renal Disease
(MDRD) study patient symptom form. Our main predictor is GI symptom score. Serum level of C-reactive protein (CRP)
was measured as well. Main outcome measures are serum albumin levels and prevalence of hypoalbuminemia.
Results: Of the participants assessed, mean serum albumin was 3.95 ± 0.46 g/dL; 12.7 % had hypoalbuminemia.
Patients with lower estimated glomerular filtration rate (eGFR) were likely to have more GI symptoms (apparent at
an eGFR <45 ml/min/1.73 m2). Patients with worse GI symptoms had lower dietary protein intake. GI symptoms,
like inflammation, were risk factors for lower serum albumin levels. However, adding GI symptom score or CRP into
the multivariable regression analysis, did not attenuate the association between lower eGFR and lower albumin or
hypoalbuminemia.
Conclusions: Increased prevalence of GI symptoms become apparent among CKD patients at relatively high eGFR
levels (45 ml/min/1.73 m2), long before ESRD. Patients with more severe GI symptoms scores are more likely to have
hypoalbuminemia. But our data do not support GI symptoms/decreased protein intake or inflammation as being the
main determinants of serum albumin level in CKD patients.
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Background
Hypoalbuminemia is well known to be an important
problem in patients with end-stage renal disease (ESRD),
where it is one of the strongest predictors for death and
other adverse outcomes [1–3]. Low serum albumin
levels are also an adverse prognostic sign in non-kidney
disease patients [4–6]. However, few studies have
focused on investigating hypoalbuminemia in patients
during earlier stages of chronic kidney disease (CKD)
[7–9]. In particular, little is known about the role of
gastrointestinal (GI) symptoms.
Prior studies of malnutrition in ESRD have empha-
sized the prevalence of anorexia and resultant reduced
oral intake. Few studies however, have examined GI
symptoms in patients with milder degrees of renal dys-
function. One paper, from the Modification of Diet in
Renal Disease (MDRD) study, reported that the preva-
lence of “uremic” symptoms such as nausea, vomiting
and anorexia actually emerge at higher glomerular filtra-
tion rate (GFR) levels than previously realized (i.e. these
were not just present in ESRD patients) [10].
Prior studies, especially in the ESRD literature, have
emphasized that serum albumin concentration correlates
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not only with lower protein intake, but also with in-
flammation, the severity of which can be assessed
using a metric such as level of C-reactive protein
(CRP), an acute phase reactant [11–13]. We therefore
undertook the current study to better understand the
potential contributions of GI symptoms and inflam-
mation on the association of kidney function and
serum albumin levels in CKD.
Methods
Study population
This was a cross-sectional analysis of baseline data from
the Chronic Renal Insufficiency Cohort (CRIC) study.
CRIC is a multi-center observational study of 3,939
adults aged 21 to 74 years old at baseline with mild to
moderate CKD with estimated GFR (eGFR) ranging
from 20–70 ml/min/1.73 m2. The eGFR was estimated
using the MDRD equation. Participants were recruited
from seven clinical centers (13 recruitment sites)
throughout the United States from 2003 through
2008. The study design, methods, baseline characteris-
tics, the inclusion and exclusion criteria have been
previously described [14, 15]. The study was approved
by the local institutional review boards at the CRIC
data coordinating center (University of Pennsylvania)
and recruitment sites (University of Pennsylvania,
John Hopkins University, University of Maryland,
University Hospitals of Cleveland Case Medical Cen-
ter, MetroHealth Medical Center, Cleveland Clinical
Foundation, St. John’s Health System, Wayne State
University, University of Michigan at Ann Arbor, Uni-
versity of Illinois at Chicago, Tulane University, Kaiser
Permanente of Northern California and University of
California, San Francisco). All CRIC participants gave
informed written consent for the collection of infor-
mation for the purpose of research.
All CRIC participants had symptoms assessed at base-
line using the MDRD study Patient Symptom Form [10]
described below. No specific dietary instructions were
given to enrollees by study investigators. After excluding
(overlapping) CRIC participants who did not complete
the Patient Symptom Form (n = 22) or had missing
serum albumin/CRP (n = 65), or missing 24-hour
urine urea, urine protein, urine albumin quantifica-
tion (n = 263) or missing height and weight informa-
tion (n = 10), our final study size was 3,599 (see
Additional file 1: Figure S1).
Assessment of GI symptoms
The MDRD Patient Symptom Form includes 23 items
covering a range of symptoms which may be related
to kidney disease, such as muscle cramps or itching.
Patients were asked about the number of days in the
past month that they had each of the symptoms
listed. If a symptom was present, patients rated the
severity of the symptom on a scale of 1 (mild, symp-
toms did not interfere with usual activities), 2 (mod-
erate, symptoms interfered somewhat with usual
activities) or 3 (severe, symptoms were so bothersome
that usual activities could not be performed). For the
current analysis we a priori decided to focus on five
of the GI symptoms which we judged to be more
likely to be associated with dietary intake, including
“A bad taste in your mouth,” “Loss of appetite,”
“Nausea or being sick to your stomach,” “Vomiting,”
and “Abdominal bloating or gas.” To create a severity
score for each symptom, we multiplied the number of
symptom days by the severity scale (i.e. higher score
represented more pronounced symptoms). We found
that all four scores were higher among patients with
lower eGFR except for “Abdominal bloating or gas”.
So our final “GI symptom score” was the summation of
the individual severity scores for “A bad taste in your
mouth”, “Loss of appetite”, “Nausea or being sick to your
stomach”, “Vomiting”. We classified a priori participants
without symptoms as the reference group for all compari-
sons and then divided the remaining participants into ter-
tiles to avoid assumptions of linear effect. (In sensitivity
analysis we did include “Abdominal bloating or gas” also
into the GI symptom score.)
Measurement of serum albumin
Serum albumin level was measured by dye-binding assay
(Ortho Clinical Diagnostics). We defined hypoalbumin-
emia as serum albumin < 3.5 g/dL [16, 17].
Assessment of other covariates
High sensitive CRP was measured by end-point nephe-
lometry (Siemens BN™ II System) [18]. Patients were
divided into three categories: CRP < 3.00 mg/L, CRP
between 3.00 and 10.00 mg/L, and CRP ≥ 10.00 mg/L
[7, 19–21].
At the baseline CRIC visit, urine urea nitrogen,
total protein and albumin excretion were determined
from a 24-hour urine collection. Dietary protein in-
take was estimated according to the following formula
[22]: dietary protein intake (g/24 h) = 6.25 × [24 h
urine urea nitrogen + 0.031 × body weight] + 24 h urine
protein. Dietary protein intake was normalized to
body weight [23, 24]. Urine urea nitrogen concentra-
tion was determined by endpoint spectrophotometric
assay (Ortho Clinical Diagnostics). Total urine protein
concentration was determined with the turbidometric
method with benzthonium chloride (Roche Diagnos-
tics) and total urine albumin was done by immuno-
turbidometric assay (Roche Diagnostics). The samples
were rejected and re-collection attempted if total
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urine volumes were below 500 ml or collection times
below 22 h or more than 26 h.
Statistical analysis
We first examined the distribution of baseline character-
istics according to categories of eGFR. Continuous vari-
ables were described as mean ± standard deviation or
median (25th-75th percentiles) where appropriate and
analyzed using analysis of variance. Categorical variables
were described using proportions and analyzed using the
χ2 test. CRP was log transformed given the skewed
distribution.
We then proceeded to undertake a series of ana-
lyses to better understand the relationship between
reduced kidney function, GI symptoms, protein in-
take, serum albumin levels, and other factors which
may affect serum albumin levels such as inflammation
(please see Fig. 1 for conceptual diagram). Logistic
regression analysis was used to estimate odds of pres-
ence of specified patient GI symptoms (yes/no) as a
function of baseline eGFR, controlling for age, gender,
race/ethnicity, diabetes diagnosis and using patients
with eGFR ≥60 ml/min/1.73 m2 as the reference
group (pathway ①). We then determined using linear
regression whether worse GI symptoms was corre-
lated with lower serum albumin (and in logistic re-
gression determined whether worse GI symptoms was
correlated with higher risk of hypoalbuminemia)
(pathway ②). We then adjusted for dietary protein
intake to determine whether poor protein intake me-
diated the association between worse GI symptoms
and lower serum albumin levels (pathway ③). In
Fig. 1 Relationship between reduced kidney function, serum albumin
levels, GI symptoms, dietary protein intake and inflammation
Table 1 Characteristics of study population by level of eGFR (ml/min/1.73 m2)
eGFR level (ml/min/1.73 m2)




≥60 (N = 370) p value
Mean age, years, mean (SD) 58.4 ± 10.9 58.8 ± 11.2 59.8 ± 10.6 58.6 ± 10.3 51.6 ± 11.0 <0.001
Men (%) 55.0 47.8 53.5 60.4 57.0 <0.001
Race/Ethnicity <0.001
White/Caucasian (%) 43.3 37.6 43.2 47.6 40.8
Black/African American (%) 41.4 40.3 40.4 41.0 48.9
Hispanic (%) 11.4 18.3 12.9 7.2 5.9
Other (%) 3.9 3.8 3.5 4.2 4.3
Diabetes mellitus (%) 48.1 54.2 54.0 42.1 33.2 <0.001
Myocardial Infarcation/Prior Revasculization (%) 22.2 24.7 24.2 21.4 13.0 <0.001
Peripheral Vascular Disease (%) 6.7 11.0 7.1 4.9 2.7 <0.001
Stroke (%) 9.7 10.6 10.7 9.9 4.1 0.001
BMI, kg/m2, mean (SD) 32.2 ± 7.8 32.1 ± 8.3 32.5 ± 7.7 32.1 ± 7.9 31.4 ± 7.1 0.1
Serum creatinine, mg/dL, mean (SD) 1.74 ± 0.57 2.56 ± 0.56 1.78 ± 0.32 1.39 ± 0.22 1.14 ± 0.20
eGFR, ml/min/1.73 m2, mean (SD) 42.9 ± 13.4 24.9 ± 3.51 37.8 ± 4.22 51.6 ± 4.23 67.5 ± 7.55
Albumin level, g/dL, mean (SD) 3.95 ± 0.46 3.86 ± 0.47 3.90 ± 0.47 4.01 ± 0.44 4.07 ± 0.40 <0.001
Hypoalbuminemia (%) 12.7 16.6 15.6 9.0 6.2 <0.001
Dietary Protein Intake, g/kg/day, mean (SD) 0.81 ± 0.31 0.78 ± 0.31 0.80 ± 0.30 0.83 ± 0.30 0.87 ± 0.35 <0.001
CRP, mg/L, median (IQR) 2.59 (1.07, 6.33) 2.83 (1.08, 6.97) 2.90 (1.20, 6.71) 2.38 (1.00, 6.23) 1.85 (0.89, 4.07) <0.001
Urine albumin, g/24 h, median (IQR) 0.06 (0.01, 0.55) 0.34 (0.05, 1.52) 0.10 (0.02, 0.71) 0.03 (0.01, 0.21) 0.01 (0.01, 0.08) <0.001













athe 4 variables are “A bad taste in your mouth?”, “Loss of appetite?”, “Nausea or being sick to your stomach?”, “Vomiting?”
Conversion factors for units: Serum creatinine in mg/dL to μmol/L, ×88.4
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parallel, we examined whether higher CRP was corre-
lated with lower serum albumin (pathway ④).
Finally, we evaluated whether worse GI symptoms and
higher CRP explained why patients with lower eGFR had
lower serum albumin or whether other mechanisms
were important (pathway ⑤). We did this by seeing if
the association between lower eGFR and serum albumin
levels was attenuated or extinguished by adjusting for GI
symptoms, CRP and other factors which may influence
serum albumin level such as 24-hour urine albumin
excretion.
All statistical analyses were conducted using IBM
SPSS Statistics 20.0 (IBM Corporation, Armonk, NY,
USA). A p-value < 0.05 was considered statistically
significant.
Regulatory approval
De-identified data for this analysis was retrieved from
the National Institutes of Diabetes and Digestive and
Kidney Disease (NIDDK) Data Repository (https://
www.niddkrepository.org/home/) after appropriate in-
stitutional review board approval was obtained (Uni-
versity of California San Francisco Committee on
Human Research IRB Number: 10–04231).
Results
The baseline characteristics of the study population
are shown in Table 1. Of the 3599 participants in our
study, the mean age was 58.4 ± 10.9 years, 55 % were
men, the mean BMI was 32.2 ± 7.8 kg/m2, mean
serum albumin was 3.95 ± 0.46 g/dL; 12.7 % had
hypoalbuminemia.
Characteristics of those who did and did not have GI
symptoms are compared in the Table 2. In general, those
with lower eGFR indeed were more likely to have GI
symptoms (Fig. 2). They also had lower serum albumin
and higher CRP levels (Table 1).
As shown in Table 3, lower eGFR was an independent
risk factor for having more severe GI symptoms even
after controlling for demographics and presence or
absence of diabetes mellitus (pathway ①).
Patients with worse GI symptoms had lower serum
albumin concentrations and higher risk of hypoalbumin-
emia in univariate regression (Table 4) (pathway ②). GI
symptoms was negatively correlated with dietary pro-
tein intake (r = −0.141, P < 0.01). And dietary protein
intake was positively correlated with serum albumin
level (r = 0.094, P < 0.01) (pathway ③). By adding diet-
ary protein intake into the regression model, we
found that the association between GI symptoms and
low albumin was slightly weakened but not abolished
(Table 4) (pathway ② +③).
Patients with higher CRP levels had lower serum
albumin concentrations. Specifically, compared with









Mean age, years, mean (SD) 59.3 ± 10.7 57.3 ± 11.0 <0.001
Men (%) 61.1 48.2 <0.001
Race/Ethnicity
White/Caucasian (%) 48.0 38.1 <0.001
Black/African American (%) 38.4 44.8
Hispanic (%) 9.1 13.9
Other (%) 4.5 3.1




Peripheral Vascular Disease (%) 5.0 8.6 <0.001
Stroke (%) 7.9 11.8 <0.001
BMI, kg/m2, mean (SD) 31.8 ± 7.3 32.6 ± 8.4 0.002
Serum creatinine, mg/dL,
mean (SD)
1.69 ± 0.52 1.79 ± 0.62 <0.001
eGFR, ml/min/1.73 m2,
mean (SD)
44.2 ± 13.0 41.4 ± 13.7 <0.001
Albumin level, g/dL,
mean (SD)
3.99 ± 0.44 3.90 ± 0.47 <0.001
Hypoalbuminemia (%) 10.2 15.5 <0.001
Dietary Protein Intake,
g/kg/day, mean (SD)
0.84 ± 0.32 0.77 ± 0.29 <0.001
CRP, mg/L, median (IQR) 2.41 (1.01, 5.68) 2.82 (1.13, 7.08) 0.003
Urine albumin, g/24 h,
median (IQR)
0.05 (0.01, 0.50) 0.09 (0.01, 0.64) <0.001
Fig. 2 Prevalence of GI symptoms across eGFR categories. The
* identifies P < 0.01 for a chi-square test among the groups with
different eGFR values
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participants with CRP <3.00 mg/L (n = 1965), those
with CRP 3.00–10.00 mg/L (n = 1200) had serum
albumin levels which were 0.05 g/dL (p = 0.003) lower
and those with CRP ≥10.00 mg/L (n = 434) had serum
albumin levels which were 0.13 g/dL (p < 0.001) lower
(pathway ④).
To examine how much GI symptoms and inflam-
mation mediated the association between lower eGFR
and hypoalbuminemia, we simultaneously controlled
for GI symptoms and CRP in a model with eGFR as
the exposure and serum albumin as the outcome. As
shown in Tables 5 and 6, in unadjusted analyses,
patients with lower eGFR had lower serum albumin
levels and higher risk of hypoalbuminemia. After
adding GI symptom score or CRP into the regression
analysis, neither factor attenuated the association be-
tween lower eGFR and lower albumin or hypoalbu-
minemia (pathway ⑤). But we found that the
association between eGFR and low albumin was
greatly weakened by adding 24-hour urine albumin
excretion into the regression model. Finally, in multi-
variable analysis, lower eGFR was an independent
risk factor for lower serum albumin and higher risk
of hypoalbuminemia after controlling for demograph-
ics and presence or absence of diabetes mellitus. But
after adding GI symptom score, CRP and 24-hour
urine albumin excretion into the fully adjusted
model, the association between lower eGFR and
lower serum albumin/higher risk of hypoalbuminemia
was basically abolished.
In sensitivity analyses, our results were similar when
we analyzed the sum of 5 rather than 4 GI symptoms
(data not shown).
Discussion
In summary, in this large cross-sectional study of
CKD patients, those with lower eGFR had a higher
burden of GI symptoms and there was an association
between burden of GI symptoms and lower serum
albumin levels. Patients with reduced eGFR also had
higher CRP levels which was associated with lower
serum albumin levels. But the reason for the hypoal-
buminemia in CKD patients does not appear to be
due to GI symptoms/decreased protein intake or
inflammation.
A diminished appetite and nausea/vomiting are clas-
sic “uremic symptoms”. However, few studies have
systematically assessed these GI symptoms among
CKD patients not on dialysis. One prior study noted
that, long before ESRD, starting at stage 3b CKD
(eGFR <45 ml/min/1.73 m2), GI symptoms such as
loss of appetite and nausea/vomiting start to emerge
[10]. We are able to extend these observations to a
more diverse cohort than the MDRD study partici-
pants who were all clinical trial enrollees and had to
exceed certain nutritional threshold in order to be
allowed to be randomized into a diet manipulation
study. Our results suggest that physicians should be
aware of the possible onset of GI symptoms relatively
Table 3 Odds Ratios for Specific GI symptoms (pathway ①) Adjusted for age, sex, race/ethnicity, diabetes
Symptom Odds Ratio (95 % CI)
eGFR ≥60 ml /min/1.73 m2
(n = 370)
eGFR 45–60 ml /min/1.73 m2
(n = 1166)
eGFR 30–45 ml /min/1.73 m2
(n = 1375)
eGFR < 30 ml /min/1.73 m2
(n = 688)
A bad taste in your mouth? 1.0 (reference) 0.99(0.75–1.32) P = 0.9 1.22(0.92–1.62) P = 0.2 1.34(0.99–1.82) P = 0.06
Loss of appetite? 1.0 (reference) 1.21(0.88–1.68) P = 0.2 1.83(1.34–2.52) P < 0.001 2.01(1.43–2.82) P < 0.001
Nausea or being sick to your
stomach?
1.0 (reference) 0.95(0.72–1.25) P = 0.7 1.24(0.95–1.63) P = 0.1 1.32(0.98–1.78) P = 0.06
Vomiting? 1.0 (reference) 1.08(0.70–1.67) P = 0.7 1.67(1.11–2.54) P = 0.02 1.76(1.13–2.75) P = 0.01
Table 4 How serum albumin levels and prevalence of hypoalbuminemia vary by GI symptoms (Pathway ② +③)
Outcomes
Absolute change in serum albumin g/dL (95 % CI) Hypoalbuminemia odds ratio (95 % CI)
Predictor GI symptom score Unadjusted Adjusted for dietary protein
intake
Unadjusted Adjusted for dietary protein
intake
None (score of 0) (n = 1897) reference reference 1.0 reference 1.0 reference




−0.06(−0.10 ~ −0.02) p = 0.004 1.44(1.09 ~ 1.89) p = 0.01 1.41(1.07 ~ 1.85) p = 0.02




−0.08(−0.12 ~ −0.04) p < 0.001 1.67(1.28 ~ 2.18) p < 0.001 1.63(1.25 ~ 2.13) p < 0.001




−0.12(−0.16 ~ −0.08) p < 0.001 1.77(1.34 ~ 2.33) p < 0.001 1.71(1.29 ~ 2.25) p < 0.001
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early in the course of CKD and take this into account
in the course of patient care.
Our study advances our understanding of the clin-
ical implications of these GI symptoms. GI symptoms
are risk factors for lower serum albumin levels in
CKD patients. It is easy and inexpensive to ask pa-
tients about GI symptoms repeatedly over time. Spon-
taneous restriction of protein intake is known to
occur in patients as CKD progresses [25, 26]. Patients
with worse GI symptoms had lower dietary protein
intake, and it seems plausible that this association
was causal (although this cannot be proven in a
cross-sectional observational study). Interestingly, con-
trolling for dietary protein intake only partly attenu-
ated the association between GI symptoms and
hypoalbuminemia, arguing that this is not that im-
portant a pathway connecting the two, although this
conclusion should be tampered by the recognition
that there is significant measurement error in both
the assessment of symptoms and the quantification of
dietary protein intake. Further studies are therefore
needed to better our understanding of the association
between GI symptoms and hypoalbuminemia.
In parallel with our examination of GI symptoms and
for comparison, we also examined the association of
CRP with serum albumin. CRP is the most frequently
measured inflammatory marker and is associated with
an increased risk of cardiovascular disease and mortality
in both the general population [27–29] and in CKD and
ESRD patients [11, 12, 30]. Our studies are consistent
with others studies enrolling participants in the range
of stage 2–4 CKD which showed that CRP levels are
higher at lower levels of GFR [31, 32]. They differ
from a report from MDRD which found no relation-
ship between levels of CRP and GFR in univariate
analysis [33]. Possibilities for the discrepancy may in-
clude the fact that MDRD was a clinical trial which
enrolled relatively healthy patients, for example ex-
cluding those with serum albumin <3.0 g/dL or body
weight <80 % standard body weight [34]. Also, few
patients with DM were enrolled [34].
When we controlled for GI symptoms and CRP, we did
not attenuate the association between lower eGFR and
lower serum albumin levels. Of note, the R2 for the model
linking dietary protein intake and CRP to serum albumin
are relatively low (both 0.01). This differs from the
Table 5 How serum albumin levels vary by eGFR (pathway ⑤)
Outcomes
Absolute change in serum albumin, g/dL (95 % CI)
Predictor eGFR
(ml/min/1.73 m2)
Unadjusted Adjusted for GI
symptom score





≥60(n = 370) reference reference reference reference reference reference
45–60 (n = 1166) −0.06 (−0.11 ~
−0.003) p = 0.04
−0.06 (−0.11 ~
−0.003) p = 0.04
−0.05 (−0.10 ~ 0.002)
p = 0.06
−0.03 (−0.08 ~ 0.02)
p = 0.2
−0.08 (−0.13 ~ −0.03)
p = 0.002
−0.03 (−0.07 ~ 0.02)
p = 0.2
30–44 (n = 1375) −0.16 (−0.22 ~
−0.11) p < 0.001
−0.16 (−0.21 ~
−0.11) p < 0.001
−0.15 (−0.21 ~ −0.10)
p < 0.001
−0.09 (−0.14 ~ −0.05)
p < 0.001
−0.16 (−0.21 ~ −0.11)
p < 0.001
−0.07 (−0.11 ~ −0.02)
p = 0.005
<30 (n = 688) −0.21 (−0.27 ~
−0.15) p < 0.001
−0.20 (−0.26 ~
−0.14) p < 0.001
−0.20 (−0.25 ~ −0.14)
p < 0.001
−0.08 (−0.13 ~ −0.03)
p = 0.003
−0.19 (−0.24 ~ −0.13)
p < 0.001
−0.04 (−0.09 ~ 0.01)
p = 0.1
aAdjusted for age, sex, race/ethnicity, diabetes
bAdjusted for age, sex, race/ethnicity, diabetes, CRP, GI symptom score, 24-hour albuminuria
Table 6 How prevalence of hypoalbuminemia varies by eGFR (pathway ⑤)
Outcomes
Hypoalbuminemia, Odds Ratio (95 % CI)
Predictor eGFR
(ml/min/1.73 m2)
Unadjusted Adjusted for GI
symptom score





≥60 (n = 370) 1.0 reference 1.0 reference 1.0 reference 1.0 reference 1.0 reference 1.0 reference
45–60 (n = 1166) 1.49 (0.94 ~ 2.38)
p = 0.09
1.50 (0.94 ~ 2.39)
p = 0.09
1.46 (0.92 ~ 2.34)
p = 0.1
1.24 (0.76 ~ 2.02)
p = 0.4
1.79 (1.11 ~ 2.91)
p = 0.02
1.30 (0.78 ~ 2.14)
p = 0.3
30–44 (n = 1375) 2.78 (1.78 ~ 4.35)
p < 0.001
2.73 (1.75 ~ 4.27)
p < 0.001
2.68 (1.72 ~ 4.19)
p < 0.001
1.86 (1.16 ~ 2.97)
p = 0.01
2.98 (1.87 ~ 4.75)
p < 0.001
1.71 (1.05 ~ 2.78)
p = 0.03
<30 (n = 688) 3.00 (1.88 ~ 4.78)
p < 0.001
2.91 (1.82 ~ 4.65)
p < 0.001
2.82 (1.77 ~ 4.51)
p < 0.001
1.36 (0.82 ~ 2.25)
p = 0.2
2.90 (1.78 ~ 4.72)
p < 0.001
1.18 (0.70 ~ 2.00)
p = 0.5
aAdjusted for age, sex, race/ethnicity, diabetes
bAdjusted for age, sex, race/ethnicity, diabetes, CRP, GI symptom score, 24-hour albuminuria
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situation in ESRD in which normalized protein catabolic
rate (nPCR) and CRP explained more of the variation in
serum albumin (R2 = 0.13) [12]. An important reason may
be that CRP levels are only mildly increased in CKD, not
that much higher than the general population [33]. In
contrast, CRP levels are more elevated in ESRD. For ex-
ample, Kaysen et al. concluded that the cross-sectional as-
sociation of albumin levels with CRP levels is much
stronger when CRP level reach >13 mg/L [30].
But in our final analysis, neither GI symptoms nor
inflammation appeared to explain why patients with
CKD at higher risk for hypoalbuminemia. We found
in contrast that 24-hour urine albumin excretion ap-
pears to be more important since by additionally
adjusting for this, we observed that the association
between eGFR and lower serum albumin level was
basically abolished. This is consistent with the result
of prior cross-sectional analyses [35, 36] and supports
the hypothesis that urinary albumin loss are in the
causal pathway linking lower eGFR and lower serum
albumin levels, although it should be noted that abso-
lute levels of 24-hour urine albumin are quite low in
CRIC participants.
Our analysis had several strengths. There are few
studies which have systemically collected data on GI
symptoms in CKD patients and we were able to re-
late this to hypoalbuminemia, an important clinical
parameter. Our study population was relatively large
with a wide range of eGFR and included a high pro-
portion of black and diabetic patients, representative
of the U.S. CKD population. GI symptoms were sys-
tematically captured using a uniform research proto-
col. Dietary protein intake was objectively measured
using 24-hour urine and not inferred from recall
which may be subject to biases.
The present study also has several limitations. First,
only one 24-hour urine sample was available to calcu-
late dietary protein intake from urinary urea nitrogen.
Second, we use CRP alone to fully adjust for the ef-
fects of inflammation. Other acute phase proteins
with longer half-lives, such as fibrinogen, α1 acid
glycoprotein, may provide additional information if
available. We may also be able to develop a more
comprehensive understanding of the inflammation-
intake paradigm by consideration of cytokines (for
example, IL-1, IL-6, TNF-α) or negative acute phase
proteins (for example, prealbumin and transferrin) in
future studies. Third, the present is a cross-sectional
study which limited inferences regarding direction of
effect. Fourth, there was no international representa-
tion and the high BMI observed may be particular to
the American CKD population. Finally, CRIC ex-
cluded patients with polycystic kidney disease, mul-
tiple myeloma and glomerular diseases on active
immunosuppression [14, 15]. So our results may not
be generalizable to those patients.
Conclusions
In conclusion, increased prevalence of GI symptoms be-
come apparent among CKD patients at relatively high
eGFR levels, long before ESRD. GI symptoms, like in-
flammation, are risk factors for lower serum albumin
levels. But the presence of GI symptoms (and inflamma-
tion) cannot fully explain the prevalence of hypoalbu-
minemia in CKD patients. More studies are required to
better understand the relationship between reduced kid-
ney function and hypoalbuminemia.
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